SD BIOTECHNOLOGIES (217480) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SD BIOTECHNOLOGIES (217480) reported revenue of 30.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202530.1 billion KRW-6.3 billion KRW-7.5 billion KRW[source]
202434.5 billion KRW-9.2 billion KRW-14.8 billion KRW[source]
202346.9 billion KRW-13.7 billion KRW-6.0 billion KRW[source]
202292.9 billion KRW-41.0 billion KRW-75.0 billion KRW[source]
2021124.7 billion KRW-34.8 billion KRW-45.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202544.7 billion KRW16.9 billion KRW27.8 billion KRW[source]
202455.3 billion KRW28.8 billion KRW26.4 billion KRW[source]
202365.9 billion KRW27.4 billion KRW38.6 billion KRW[source]
202267.9 billion KRW62.7 billion KRW5.2 billion KRW[source]
2021112.2 billion KRW69.5 billion KRW42.7 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-5.1 billion KRW22.4 billion KRW-13.4 billion KRW[source]
2024-4.3 billion KRW-10.0 billion KRW-2.9 billion KRW[source]
2023-3.1 billion KRW5.6 billion KRW9.4 billion KRW[source]
2022-15.4 billion KRW-2.1 billion KRW10.2 billion KRW[source]
2021-17.3 billion KRW-2.0 billion KRW20.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice